[go: up one dir, main page]

WO2013102929A4 - Nouveaux composés pour le traitement du diabète, de l'obésité ou de troubles associés - Google Patents

Nouveaux composés pour le traitement du diabète, de l'obésité ou de troubles associés Download PDF

Info

Publication number
WO2013102929A4
WO2013102929A4 PCT/IN2012/000821 IN2012000821W WO2013102929A4 WO 2013102929 A4 WO2013102929 A4 WO 2013102929A4 IN 2012000821 W IN2012000821 W IN 2012000821W WO 2013102929 A4 WO2013102929 A4 WO 2013102929A4
Authority
WO
WIPO (PCT)
Prior art keywords
imidazol
fluorophenyl
propan
thio
dimethoxyphenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IN2012/000821
Other languages
English (en)
Other versions
WO2013102929A1 (fr
Inventor
Sameer Agarwal
Ranjit C. Desai
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Zydus Lifesciences Ltd
Original Assignee
Cadila Healthcare Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cadila Healthcare Ltd filed Critical Cadila Healthcare Ltd
Publication of WO2013102929A1 publication Critical patent/WO2013102929A1/fr
Publication of WO2013102929A4 publication Critical patent/WO2013102929A4/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/84—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne des composés de la formule générale (I), leurs sels pharmaceutiquement acceptables, leurs solvates pharmaceutiquement acceptables, des énantiomères, des diastéréomères, des promédicaments, leur N-oxyde, des métabolites, des polymorphes, l'utilisation de ces composés en médecine et les produits intermédiaires employés dans leur préparation.
PCT/IN2012/000821 2011-12-26 2012-12-17 Nouveaux composés pour le traitement du diabète, de l'obésité ou de troubles associés Ceased WO2013102929A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN3656/MUM/2011 2011-12-26
IN3656MU2011 2011-12-26

Publications (2)

Publication Number Publication Date
WO2013102929A1 WO2013102929A1 (fr) 2013-07-11
WO2013102929A4 true WO2013102929A4 (fr) 2013-09-19

Family

ID=48048113

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IN2012/000821 Ceased WO2013102929A1 (fr) 2011-12-26 2012-12-17 Nouveaux composés pour le traitement du diabète, de l'obésité ou de troubles associés

Country Status (1)

Country Link
WO (1) WO2013102929A1 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10251870B2 (en) 2015-03-06 2019-04-09 Stc.Unm Method for treating obesity, diabetes, cardiovascular and kidney diseases by regulating GPR30/GPER activity

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004043468A1 (fr) 2002-11-12 2004-05-27 Takeda Pharmaceutical Company Limited Procede de criblage
WO2004067008A1 (fr) 2003-01-28 2004-08-12 Takeda Pharmaceutical Company Limited Agonistes de recepteurs
US7368467B2 (en) * 2004-03-08 2008-05-06 Wyeth Ion channel modulators
US20080031968A1 (en) 2005-04-01 2008-02-07 The Brigham And Women's Hospital, Inc. Methods for increasing cellular energy expenditure
WO2008067222A1 (fr) 2006-11-28 2008-06-05 Kalypsys, Inc. Modulateurs hétérocycliques de tgr5
US20090035306A1 (en) 2006-11-29 2009-02-05 Kalypsys, Inc. Quinazolinone modulators of tgr5
EP2112995B1 (fr) 2007-01-19 2013-07-31 Intercept Pharmaceuticals, Inc. Acides biliares substitues en 23 utiles comme modulateurs de tgr5 et leurs methodes d'utilisation
US20080221161A1 (en) 2007-02-09 2008-09-11 Kalypsys, Inc. Heterocyclic modulators of tgr5 for treatment of disease
WO2010014739A2 (fr) 2008-07-29 2010-02-04 Kalypsys, Inc. Modulateurs hétérocycliques du tgr5
WO2010016846A1 (fr) 2008-08-08 2010-02-11 Kalypsys, Inc. Modulateurs hétérocycliques de tgr5 pour le traitement d'une maladie
AR075255A1 (es) 2009-02-12 2011-03-16 Exelixis Inc Derivados diazolicos y/o triazolicos agonistas de receptores tgr5 acoplado a proteina g, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento de la obesidad, diabetes y otros trastornos metabolicos.
EP2509960A1 (fr) 2009-12-11 2012-10-17 Exelixis, Inc. Agonistes de tgr5
US8987307B2 (en) 2011-03-03 2015-03-24 Hoffmann-La Roche Inc. 3-amino-pyridines as GPBAR1 agonists

Also Published As

Publication number Publication date
WO2013102929A1 (fr) 2013-07-11

Similar Documents

Publication Publication Date Title
JP5966014B2 (ja) 新規トリフルオロメチル−オキサジアゾール誘導体および疾患の処置におけるその使用
JP2007520520A5 (fr)
RU2010126056A (ru) Органические соединения
ES2535244T3 (es) Compuestos heterocíclicos adecuados para el tratamiento de dislipidemia
RU2014103587A (ru) Производные циклических аминов в качестве антагонистов рецептора ер4
RU2009133259A (ru) Производные пиразола в качестве ингибиторов 11-бета-hsd1
NO20084659L (no) Ko-krystall av C-glucosidderivat og L-prolin
RU2007134380A (ru) Антибактериальные производные пиперидина
US11958844B2 (en) 1,3,4-oxadiazole derivative compounds as histone deacetylase 6 inhibitor, and pharmaceutical composition comprising the same
NZ590355A (en) Stat3 inhibitor containing quinolinecarboxamide derivative as active ingredient
CA2674436A1 (fr) Indazoles a substitution amide utilises comme inhibiteurs de la poly(adp-ribose)polymerase (parp)
RU2005117789A (ru) Производные 4,5-диарилтиазола в качестве лигандов св-1
US11649237B2 (en) Substituted imidazo[1,5-a]pyrazines for IRE1 inhibition
RU2011104223A (ru) Азотсодержащее ароматическое гетероциклическое соединение
AR083019A1 (es) Uso de un compuesto de [3-(1-(1h-imidazol-4-il)etil)-2-metilfenil]metanol para preparar un medicamento util para tratar enfermedades de la retina, articulo de fabricacion y composicion farmaceutica que lo comprenden
CN102652135A (zh) 脂肪酸酰胺水解酶的含氮杂环抑制剂
CA2557648A1 (fr) Modulateurs de la fonction canal ionique
RU2006133373A (ru) Производные имидазолина, обладающие св1-антагонистической активностью
EA201270266A1 (ru) Гетероциклические соединения
RU2006138426A (ru) Производные тиазолопиридина, содержащие их фармацевтические композиции и способы лечения состояний, опосредованных глюкокиназой
RU2014123784A (ru) Новые производные пирролидина в качестве ингибиторов катепсина
US8080570B2 (en) α2B and α2C agonists
WO2013102929A4 (fr) Nouveaux composés pour le traitement du diabète, de l'obésité ou de troubles associés
US8716292B2 (en) Riminophenazines with 2-(heteroaryl)amino substituents and their anti-microbial activity
US9309232B2 (en) Synthesis of novel inhibitors of isoprenoid biosynthesis

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 12839193

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase in:

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 12839193

Country of ref document: EP

Kind code of ref document: A1